Annual Report

Fresh off record profits, World Gym details its strategy for global growth, betting on AI health platforms and high-margin services to reshape the industry.

Amid private credit turmoil, SLR Investment Corp. posts solid 2025 results, leveraging a strategic pivot to asset-based lending for stability and returns.

AI marketing firm Zeta Global smashes records for the 18th straight quarter, raising guidance and projecting its first full year of GAAP profitability.

Fueled by policy incentives and strong demand, First Solar reports robust 2025 growth and accelerates its US factory expansion, cementing its market leadership.

Primoris Services Corp. posted a record $7.6B revenue for 2025, but a Q4 profit dip and project hurdles hint at challenges in its booming renewables arm.

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

Appian flips from a major loss to GAAP profitability in 2025, driven by strong cloud revenue, key AI contracts, and a positive outlook for 2026.

As Cherry Hill Mortgage preps its 2025 results, investors eye dividends and strategy amid high interest rates and a challenging housing market.

Riding a wave of innovation and strategic shifts, the cruise wellness leader posts record earnings and projects over $1B in 2026 revenue.

Hecla Mining posts a record $1.4B year, slashes debt, and sells a major gold mine to double down on its strategy to dominate the North American silver market.

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

Essent Group boosts its dividend after a strong 2025, returning $700M to shareholders while making a strategic leap into the global P&C reinsurance market.

The retail REIT reports record-breaking leasing and strong profits for 2025, while executing a strategic portfolio overhaul and setting a confident tone for 2026.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

Skycorp Solar reported a 27% revenue surge driven by global expansion, but intense competition and rising costs led to a surprising net loss.

With major conferences ahead, clinical-stage MBX Biosciences aims to impress investors with its promising peptide therapies for endocrine and metabolic disorders.

TruGolf accelerates its stock repurchase program, signaling faith in its future as it unveils new AI-powered tech in a booming indoor golf market.